Crinetics Pharmaceuticals announced the addition of Ajay Madan, PhD, DABT, as the Vice President of Development. Dr. Madan has a distinguished career in drug development as former VP of Preclinical Development at Neurocrine Biosciences and CSO at XenoTech. “It’s exciting to join the company at such a crucial time as we prepare to move our first program into the clinic,” said Dr. Madan. Crinetics Pharmaceuticals, Inc. is a San Diego company that discovers and develops novel therapeutics targeting peptide hormone receptors for the treatment of endocrine-related diseases and cancers.